Above all, these findings suggest that targeting multiple cell death key sites would be more effective than single therapy approach and targeting RIPK1 may provide an promising therapeutic strategy for the treatment of neurodegenerative diseases [215]. This evidence concerns the gene RIPK1 and neurodegenerative disease.